Novartis’ Afinitor Ambitions Set Back By Phase III Liver Cancer Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Announcing the failure of the Phase III EVOLVE-1 study of Afinitor in liver cancer, Novartis says that current approvals won’t be affected and that it plans to press on with Phase III studies in other indications.